David Liberg

Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides

Per Björk, Anders Björk, Thomas Vogl et al. · PLoS Biology · 2009 · 352 citations · Full text

Clinical Immunology, Drug Target, Immunology +20

Ikaros DNA-Binding Proteins as Integral Components of B Cell Developmental-Stage-Specific Regulatory Circuits

Elizabeth C. Thompson, Bradley S. Cobb, Pierangela Sabbattini et al. · Immunity · 2007 · 195 citations · Full text

Integral Components, Signal Transduction, Developmental Biology +12

S100A9 Interaction with TLR4 Promotes Tumor Growth

Eva Källberg, Thomas Vogl, David Liberg et al. · PLoS ONE · 2012 · 138 citations · Full text

Early B-Cell Factor (O/E-1) Is a Promoter of Adipogenesis and Involved in Control of Genes Important for Terminal Adipocyte Differentiation

Peter Aåkerblad, Ulrika Lind, David Liberg et al. · Molecular and Cellular Biology · 2002 · 112 citations · Full text

Metabolic Syndrome, Systems Biology, Developmental Biology +14

Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment

Anders Olsson, Jessica Nakhlé, Anette Sundstedt et al. · Journal for ImmunoTherapy of Cancer · 2015 · 79 citations · Full text